RxDoctor Payments DataLook up a doctor →

David Henderson

Medical · Morehead City, NCNPI 1578582912

Payments from drug & device makers

$10,437in general payments, 2019–2025

Across 566 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Lilly USA, LLC$681
  • GSK$597
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$10,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,437 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$113,368
Medicare patients
329
Services billed
2,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$111,588
EliquisApixaban95$76,873
JardianceEmpagliflozin61$57,443
FarxigaDapagliflozin Propanediol85$55,734
MounjaroTirzepatide39$53,200
Tresiba Flextouch U-200Insulin Degludec17$35,672
TrulicityDulaglutide25$35,318
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,558
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$20,427
Repatha SureclickEvolocumab14$17,041
UbrelvyUbrogepant11$16,867
XareltoRivaroxaban23$16,550
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,371
VascepaIcosapent Ethyl13$5,862
Ezetimibe322$4,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,204$111,588109 claims
Lilly USA, LLCMounjaro, Trulicity$681$88,51864 claims
PfizerEliquis$421$76,87395 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,188$76,162105 claims
Boehringer IngelheimJardiance$225$57,44361 claims
GSKTrelegy Ellipta$597$24,55833 claims
AbbVieUbrelvy$1,285$16,86711 claims
Johnson & JohnsonXarelto$54$16,55023 claims
MerckJanuvia$247$2,08312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Morehead City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →